Goldman Sachs Downgrades Cepheid To Neutral, $35 PT

July 6, 2011 7:15 AM | 6 seconds read |
Goldman Sachs has downgraded Cepheid CPHD from Buy to Neutral and maintains its $35 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: DowngradesPrice TargetAnalyst RatingsBiotechnologyGoldman SachsHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!